Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.66 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | AHCY | P23526 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nb-001 SCHEMBL29886392 | 1.00 | ADCY1 (1.00) | ADCY1ALDH1A1ADORA2AADORA1ADCY5 | |
| SCHEMBL29087636 | 0.99 | ADCY1 (0.97) | ADCY1ALDH1A1ADORA2AADORA1ADCY5 | |
| SCHEMBL29087571 | 0.88 | ALDH1A1 (0.79) | ADCY1ALDH1A1ADORA2AADORA1ADCY5 | |
| SCHEMBL8467390 | 0.86 | ADORA2A (0.88) | ADCY1ALDH1A1ADORA2AADORA1ADCY5 | |
| SCHEMBL29930375 | 0.86 | ALDH1A1 (0.97) | ADCY1ALDH1A1ADORA2AADORA1ADCY5 | |
| SCHEMBL19553487 | 0.85 | ADORA2A (0.91) | ADCY1ADORA2AADORA1ADCY5ADORA2B | |
| SCHEMBL20558510 | 0.85 | ADCY1 (0.73) | ADCY1ALDH1A1ADORA2AADORA1ADCY5 | |
| SCHEMBL1635576 | 0.83 | ADORA2A (1.00) | ADCY1ADORA2AADORA1ADCY5ADORA2B | |
| SCHEMBL29459142 | 0.80 | ADORA2A (1.00) | ADCY1ADORA2AADORA1ADCY5ADORA2B | |
| SCHEMBL984944 | 0.80 | ADORA2A (1.00) | ADCY1ADORA2AADORA1ADCY5ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279200-B1 | CRYSTAL OF 5-((2-(6-AMINO)-9H-PURIN-9-YL)ETHYL)AMINO)PENTAN-1-OL | FOREVER CHEER HOLDING LTD (HK) | 2024-09-04 | — | — | EP | claimed |
| CN-114984020-B | Use of adenylate cyclase inhibitors for the treatment of epilepsy and related disorders | 永展控股有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-115998745-B | Use of an adenylate cyclase inhibitor NB001 in the manufacture of a medicament for the treatment of pain and anxiety associated with Parkinson's disease | 永展控股有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-114931561-B | Capsule composition for treating chronic pain and preparation method thereof | 青岛永展医药科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-115998745-A | Use of an adenylate cyclase inhibitor NB001 in the manufacture of a medicament for the treatment of pain and anxiety associated with Parkinson's disease | 永展控股有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-115990167-A | Application of adenylate cyclase inhibitor NB001 in preparation of medicine for treating migraine and anxiety | 永展控股有限公司 | 2023-04-21 | — | — | CN | claimed |
| US-11541060-B2 | Pharmaceutical compositions for treating pain | Forever Cheer Holding Limited (HK) | 2023-01-03 | — | — | US | claimed |
| CN-114984020-A | Use of adenylate cyclase inhibitors for the treatment of epilepsy and related disorders | 永展控股有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-114931561-A | Capsule composition for treating chronic pain and preparation method thereof | 青岛永展医药科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| EP-3403674-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | FOREVER CHEER INTERNATIONAL LTD (HK) | 2021-06-30 | — | — | EP | claimed |
| US-20200268766-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | Forever Cheer Holding Limited (HK) | 2020-08-27 | — | — | US | claimed |
| US-20180333420-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | FOREVER CHEER INTERNATIONAL LTD (HK) | 2018-11-22 | — | — | US | claimed |
| EP-3403674-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | Forever Cheer International Limited (HK) | 2018-11-21 | — | — | EP | claimed |
| US-20160257930-A1 | NEURONAL STEM CELL DIFFERENTIATION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-09-08 | — | — | US | claimed |
| EP-3058064-A1 | NEURONAL STEM CELL DIFFERENTIATION | University College Cardiff Consultants Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| WO-2015055987-A1 | NEURONAL STEM CELL DIFFERENTIATION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2015-04-23 | — | — | WO | claimed |
| CN-122020546-A | Port group multisource heterogeneous data fusion and transportation channel digitizing method and system | 交通运输部规划研究院 | 2026-05-12 | — | — | CN | disclosed |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | HALOZYME, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20090233922-A1 | Method for Treating Neuronal and Non-Neuronal Pain | FOREVER CHEER INTERNATIONAL LIMITED (HK) | 2009-09-17 | — | — | US | disclosed |
| WO-2007041863-A1 | METHOD FOR TREATING NEURONAL AND NON-NEURONAL PAIN | ZHUO MIN (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268766-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | OPRM1, OPRL1, OPRD1 | ADCY1 37/4885ALDH1A1 384/4885ADORA2A 511/4885 |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | CD22, CD2, CD44 | ADCY1 2228/4885ALDH1A1 417/4885ADORA2A 1282/4885 |
| US-11541060-B2 | Pharmaceutical compositions for treating pain | OPRM1, OPRL1, OPRD1 | ADCY1 37/4885ALDH1A1 384/4885ADORA2A 511/4885 |
| US-20090233922-A1 | Method for Treating Neuronal and Non-Neuronal Pain | OPRL1, ADCY1, GRIN1 | ADCY1 2/4885ALDH1A1 603/4885ADORA2A 704/4885 |
| US-20180333420-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | OPRM1, OPRL1, OPRD1 | ADCY1 37/4885ALDH1A1 384/4885ADORA2A 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.